Metabolomic Diagnostics Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.3M
- Investors
-
1
Metabolomic Diagnostics General Information
Description
Developer of a mass spectrometry-based diagnostic platform designed to perform biomarker analysis. The company's platform can analyze multiple biomarkers in a single run, allowing for the simultaneous detection and quantification of many different compounds, enabling researchers to derive meaningful insights for disease diagnosis and risk prediction.
Contact Information
Website
www.metabolomicdiagnostics.com(Operating Subsidiary)
Corporate Office
- Hoffmann Park
- Inchera
- Little Island T45 YX04
- Cork
- Ireland
Corporate Office
- Hoffmann Park
- Inchera
- Little Island T45 YX04
- Cork
- Ireland
Metabolomic Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 24-Sep-2024 | $1.3M | Completed | Generating Revenue | ||
| 8. Later Stage VC | 14-Dec-2023 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 01-Jan-2021 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 02-Oct-2020 | Completed | Generating Revenue | |||
| 5. Grant | 09-Apr-2018 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 05-Apr-2018 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 16-Jun-2016 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 11-Feb-2015 | $855K | $1.97M | Completed | Startup | |
| 1. Seed Round | 01-Dec-2013 | $1.11M | $1.11M | Completed | Startup |
Metabolomic Diagnostics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 Preference | ||||||||
| Series A1 Preference | ||||||||
| Series A1 Preference | ||||||||
| Series A1 Preference | ||||||||
| Series A1 Preference | ||||||||
| Convertible Preference | ||||||||
| Ordinary | ||||||||
| Convertible Preference | ||||||||
| Convertible Preference | 9,865 | $0.010874 | $82.67 | $82.67 | 1x | $82.67 | 6.66% | |
| Ordinary | 987 | $0.010874 | $82.63 | $82.63 | 1x | $82.63 | 0.67% |
Metabolomic Diagnostics Comparisons
Industry
Financing
Details
Metabolomic Diagnostics Competitors (1)
One of Metabolomic Diagnostics’s competitors is CirculoGene, a Venture Capital-Backed company based in Birmingham, AL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CirculoGene | Venture Capital-Backed | Birmingham, AL |
Metabolomic Diagnostics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Metabolomic Diagnostics Patents
Metabolomic Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023379086-A1 | A method of early prediction of risk of pre-term pre-eclampsia in specific population cohorts | Pending | 10-Nov-2022 | ||
| EP-4616198-A1 | A method of early prediction of risk of pre-term pre-eclampsia in specific population cohorts | Pending | 10-Nov-2022 | ||
| US-20260194535-A1 | A method of early prediction of risk of pre-term pre-eclampsia in specific population cohorts | Pending | 10-Nov-2022 | ||
| WO-2024099769-A1 | A method of early prediction of risk of pre-term pre-eclampsia in specific population cohorts | Inactive | 10-Nov-2022 | ||
| GB-202011592-D0 | Pediction of pre-eclampsia | Inactive | 27-Jul-2020 |
Metabolomic Diagnostics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Metabolomic Diagnostics Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AIB Start-Up Academy | Accelerator/Incubator | Minority | ||
| Agilent Technologies | Corporation | Minority | ||
| Enterprise Equity Venture Capital | Venture Capital | Minority | ||
| Enterprise Ireland | Growth/Expansion | Minority | ||
| Horizon 2020 | Government |
Metabolomic Diagnostics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Inform Bioscience | Cork, Ireland | 2014 |
Metabolomic Diagnostics FAQs
-
When was Metabolomic Diagnostics founded?
Metabolomic Diagnostics was founded in 2011.
-
Where is Metabolomic Diagnostics headquartered?
Metabolomic Diagnostics is headquartered in Little Island, Ireland.
-
What is the size of Metabolomic Diagnostics?
Metabolomic Diagnostics has 11 total employees.
-
What industry is Metabolomic Diagnostics in?
Metabolomic Diagnostics’s primary industry is Decision/Risk Analysis.
-
Is Metabolomic Diagnostics a private or public company?
Metabolomic Diagnostics is a Private company.
-
What is the current valuation of Metabolomic Diagnostics?
The current valuation of Metabolomic Diagnostics is .
-
What is Metabolomic Diagnostics’s current revenue?
The current revenue for Metabolomic Diagnostics is .
-
How much funding has Metabolomic Diagnostics raised over time?
Metabolomic Diagnostics has raised $9.3M.
-
Who are Metabolomic Diagnostics’s investors?
AIB Start-Up Academy, Agilent Technologies, Enterprise Equity Venture Capital, Enterprise Ireland, and Horizon 2020 are 5 of 9 investors who have invested in Metabolomic Diagnostics.
-
Who are Metabolomic Diagnostics’s competitors?
CirculoGene is a competitor of Metabolomic Diagnostics.
-
When was Metabolomic Diagnostics acquired?
Metabolomic Diagnostics was acquired on 24-Sep-2024.
-
Who acquired Metabolomic Diagnostics?
Metabolomic Diagnostics was acquired by Trinity Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
